Literature DB >> 31897672

Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.

Malgorzata Banys-Paluchowski1, Ines Verena Gruber2, Andreas Hartkopf2, Peter Paluchowski3, Natalia Krawczyk4, Mario Marx2,5, Sara Brucker2, Markus Hahn2.   

Abstract

PURPOSE: Data on the optimal treatment strategy for patients undergoing neoadjuvant therapy (NAT) who initially presented with metastatic nodes and convert to node-negative disease (cN+ → ycN0) are limited. Since NAT leads to axillary downstaging in 20-60% of patients, the question arises whether these patients might be offered less-invasive procedures than axillary dissection, such as sentinel node biopsy or targeted removal of lymph nodes marked before therapy.
METHODS: We performed a systematic review of clinical studies on the use of axillary ultrasound for prediction of response to NAT and ultrasound-guided marking of metastatic nodes for targeted axillary dissection.
RESULTS: The sensitivity of ultrasound for prediction of residual node metastasis was higher than that of clinical examination and MRI/PET in most studies; specificity ranged in large trials from 37 to 92%. The diagnostic performance of ultrasound after NAT seems to be associated with tumor subtype: the positive predictive value was highest in luminal, the negative in triple-negative tumors. Several trials evaluated the usefulness of ultrasound for targeted axillary dissection. Before NAT, nodes were most commonly marked using ultrasound-guided clip placement, followed by ultrasound-guided placement of a radioactive seed. After chemotherapy, the clip was detected on ultrasound in 72-83% of patients; a comparison of sonographic visibility of different clips is lacking. Detection rate after radioactive seed placement was ca. 97%.
CONCLUSION: In conclusion, ultrasound improves prediction of axillary response to treatment in comparison to physical examination and serves as a reliable guiding tool for marking of target lymph nodes before the start of treatment. High quality and standardization of the examination is crucial for selection of patients for less-invasive surgery.

Entities:  

Keywords:  Axillary ultrasound; Breast cancer; Clipped lymph node; Neoadjuvant therapy; Targeted axillary dissection; Therapy response

Mesh:

Year:  2020        PMID: 31897672     DOI: 10.1007/s00404-019-05428-x

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  12 in total

1.  Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Authors:  Amparo Garcia-Tejedor; Sergi Fernandez-Gonzalez; Raul Ortega; Miguel Gil-Gil; Hector Perez-Montero; Eulalia Fernandez-Montolí; Agostina Stradella; Sabela Recalde; Teresa Soler; Anna Petit; Maria Teresa Bajen; Ana Benitez; Anna Guma; Miriam Campos; Maria J Pla; Evelyn Martinez; Maria Laplana; Sonia Pernas; Diana Perez-Sildekova; Isabel Catala; Jordi Ponce; Catalina Falo
Journal:  Breast Cancer Res Treat       Date:  2020-10-17       Impact factor: 4.872

2.  Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.

Authors:  Vishnu Prasad Pulappadi; Shashi Paul; Smriti Hari; Ekta Dhamija; Smita Manchanda; Kamal Kataria; Sandeep Mathur; Kalaivani Mani; Ajay Gogia; Svs Deo
Journal:  Br J Radiol       Date:  2021-09-07       Impact factor: 3.039

3.  Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey.

Authors:  Maggie Banys-Paluchowski; Michael Untch; Natalia Krawczyk; Maria Thurmann; Thorsten Kühn; Jalid Sehouli; Maria Luisa Gasparri; Jana de Boniface; Oreste Davide Gentilini; Elmar Stickeler; Nina Ditsch; Achim Rody; Peter Paluchowski; Jens-Uwe Blohmer
Journal:  Arch Gynecol Obstet       Date:  2022-10-10       Impact factor: 2.493

4.  Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.

Authors:  Minyan Chen; Shengmei Li; Meng Huang; Jingjing Guo; Xuan Huang; Wenhui Guo; Lili Chen; Yuxiang Lin; Lisa Jacobs; Chuan Wang; Fangmeng Fu
Journal:  Breast Cancer Res Treat       Date:  2022-09-13       Impact factor: 4.624

5.  Combining conventional ultrasound and sonoelastography to predict axillary status after neoadjuvant chemotherapy for breast cancer.

Authors:  Jia-Xin Huang; Shi-Yang Lin; Yan Ou; Cai-Gou Shi; Yuan Zhong; Ming-Jie Wei; Xiao-Qing Pei
Journal:  Eur Radiol       Date:  2022-04-02       Impact factor: 7.034

Review 6.  A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.

Authors:  Sonal Gandhi; Muriel Brackstone; Nicole J Look Hong; Debjani Grenier; Elysia Donovan; Fang-I Lu; Mia Skarpathiotakis; Justin Lee; Jean-Francois Boileau; Francisco Perera; Christine Simmons; Anil A Joy; William T Tran
Journal:  Breast Cancer Res Treat       Date:  2022-02-28       Impact factor: 4.872

7.  Formosanin C promotes the curative efficacy of ultrasound-guided radiofrequency ablation in a mouse model of breast cancer.

Authors:  Zhe Chen; Jing Li; Qianqian Cui; Fuyuan Li; Gaiying Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 8.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

Authors:  Maggie Banys-Paluchowski; Maria Luisa Gasparri; Jana de Boniface; Oreste Gentilini; Elmar Stickeler; Steffi Hartmann; Marc Thill; Isabel T Rubio; Rosa Di Micco; Eduard-Alexandru Bonci; Laura Niinikoski; Michalis Kontos; Guldeniz Karadeniz Cakmak; Michael Hauptmann; Florentia Peintinger; David Pinto; Zoltan Matrai; Dawid Murawa; Geeta Kadayaprath; Lukas Dostalek; Helidon Nina; Petr Krivorotko; Jean-Marc Classe; Ellen Schlichting; Matilda Appelgren; Peter Paluchowski; Christine Solbach; Jens-Uwe Blohmer; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 9.  Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound.

Authors:  Michael Y Chen; William E Gillanders
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-05-17

10.  Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axilla.

Authors:  Selin Guergan; Uta Hoopmann; Carmen Roehm; Bettina Boeer; Regina Fugunt; Gisela Helms; Anna Seller; Mario Marx; Ernst Oberlechner; Andreas Hartkopf; Heike Preibsch; Sara Brucker; Diethelm Wallwiener; Markus Hahn; Ines Verena Gruber
Journal:  Arch Gynecol Obstet       Date:  2021-06-17       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.